IP Explained: Four key takeaways from new Bayh-Dole white paper
By Tom Wilbur | February 19, 2020
2020 marks the 40th anniversary of the Bayh-Dole Act being signed into law. The Bayh-Dole Act laid the foundation for effective technology transfer that modernized the U.S. economy, set a global...
Read More
IP Explained: By the Numbers: How reliable IP protections promote a strong U.S. economy
By Tom Wilbur | November 4, 2019
The U.S. biopharmaceutical industry depends on predictable and reliable intellectual property (IP) protections, including patents, to maintain its role as the global leader in biopharmaceutical...
Read More
IP Explained: FACT CHECK: March-In Authority and the Bayh-Dole Act
By Tom Wilbur | October 9, 2019
In our last IP Explained post, we outlined how the Bayh-Dole Act laid the foundation for effective technology transfer across industries in the United States and helps foster continued medical...
Read More
IP Explained: Four things to know about the Bayh-Dole Act
By Tom Wilbur | September 13, 2019
Thanks in large part to strong intellectual property protections – including policies that incentivize public and private investments in research and development (R&D) – the United States is the ...
Read More
IP Explained: Three forms of IP protections for medicines
By Tom Wilbur | August 27, 2019
Intellectual property (IP) protections for the biopharmaceutical sector provide incentives that help to promote the discovery and development of life-saving medicines for patients and foster a...
Read More
IP Explained: How patents support innovation throughout the biopharmaceutical lifecycle
By Tom Wilbur | August 6, 2019
Patents are unique in that they are a form of IP protection established in the U.S. Constitution that grants inventors the right to their inventions without others being able to make, use or sell...
Read More
IP Explained: Understanding biopharmaceutical innovation
By Andrew Powaleny | July 30, 2019
Over the past 25 years, prescription medicines have transformed the trajectory of many debilitating diseases and conditions, including heart disease, HIV/AIDS, cancer and hepatitis C, resulting in...
Read More
IP Explained: Why IP protections are important for biologic medicines
By Tom Wilbur | July 18, 2019
Biologics are cutting-edge therapies that treat or cure some of the most challenging and costly diseases. These medicines are created from living organisms through highly complex manufacturing...
Read More
IP Explained: What is Section 101 and why reforms are needed
By Tom Wilbur | June 26, 2019
In today’s IP Explained post, we’re taking a closer look at Section 101 of the United States Patent Act and how proposed reforms could both level the playing field for innovators across all...
Read More
IP Explained: How Hatch-Waxman successfully balances affordability and innovation
By Tom Wilbur | May 22, 2019
For three decades, The Drug Price Competition and Patent Term Restoration Act, more commonly known as the Hatch-Waxman Act, has fostered innovation, spurred competition and helped the United...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
